Phaseline

Companies › Hangzhou SynRx Therapeutics Biomedical Technology

Hangzhou SynRx Therapeutics Biomedical Technology: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SYN818
PARP inhibitor
PARP1Phase 1Advanced Solid Cancer; Metastatic Solid TumorDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06666270SYN818Phase 1Advanced Solid CancerOncologyDec 2026
NCT07156253SYN818Phase 1Metastatic Solid TumorOncologyAug 2028

Targets

PARP1 (1)

Companies with the same targets

AstraZeneca Eikon Therapeutics Haisco Pharmaceutical Group Merck & Co. (MSD) Nerviano Medical Sciences Pfizer Johnson & Johnson (Janssen) Jiangsu Hansoh Pharmaceutical Chia Tai Tianqing Pharmaceutical Group GSK

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.